BASEL, Switzerland, October 07, 2025 / Biotech Newswire / --

瑞士巴塞尔，2025年10月7日 /生物技术新闻社/ --

CELONIC GROUP

赛洛尼克集团

, one of the leading “pureplay” Biologics CDMO, and the

，作为领先的“纯”生物制品合同开发和制造组织（CDMO）之一，以及

Carbogen Amcis Group

卡博根阿姆西斯集团

, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN AMCIS’s expertise in payload synthesis, conjugation, and sterile fill-finish, creating a seamless, end-to-end platform for ADC innovators..

，一家领先的制药工艺开发和活性药物成分（API）制造公司，今天宣布了一项战略合作伙伴关系，提供一个完全集成的抗体-药物偶联物（ADC）开发和制造解决方案。该联盟结合了Celonic先进的生物制品能力与CARBOGEN AMCIS在有效载荷合成、偶联和无菌灌装方面的专业知识，为ADC创新者打造了一个无缝的端到端平台。

This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch..

该合作伙伴关系满足了生物制药领域的一个关键需求，ADC开发的复杂性常常需要多个供应商之间的协作。通过结合双方的优势，Celonic和CARBOGEN AMCIS旨在简化供应链、加快进程，并支持客户从早期开发到商业上市的全过程。

“This strategic alliance is a direct response to the evolving needs of ADC innovators,”

“这一战略联盟是对ADC创新者不断变化的需求的直接回应，”

said Dr. Samanta Cimitan, CEO of Celonic Group.

塞洛尼克集团首席执行官萨曼塔·奇米坦博士说。

“By integrating Celonic’s advanced biologics platforms with CARBOGEN AMCIS’s world-class payload and conjugation capabilities, we’re enabling a fully harmonised development and manufacturing pathway, from DNA to drug product. It’s a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners.”.

“通过将Celonic先进的生物制品平台与CARBOGEN AMCIS世界级的有效载荷和偶联能力相结合，我们实现了从DNA到药品的全程协调开发和生产路径。这是一个可扩展、合规且商业上成熟的解决方案，旨在加速创新并降低我们合作伙伴的复杂性。”

Investing where it matters:

投资于关键领域：

“The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility,”

“新的靶向癌症治疗药物激发了对ADC不断增长的需求，这一联盟使我们能够以无与伦比的技术专长和运营敏捷性来满足这一需求。”

said Stephan Fritschi, CEO of Carbogen Amcis Group.

Carbogen Amcis集团首席执行官 Stephan Fritschi 表示。

“Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.”

“我们共同提供全面的ADC开发服务，流程简化、规模可扩展，并且符合全球标准。”

“For more than 2 decades now we’ve been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end‑to‑end ADC path—from cell line to commercial fill‑finish—under one coordinated platform,”.

“二十多年来，我们一直是连接子和有效载荷开发的首选合作伙伴，直到现在，通过客户提供的单克隆抗体，实现了精准偶联。我们非常高兴的是，从今以后，通过与Celonic的合作，创新者将获得一个无缝的、端到端的ADC路径——从细胞系到商业填充完成——全部在一个协调的平台下进行。”

adds Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group.

Dishman和Carbogen Amcis集团的全球董事总经理阿尔皮特·维亚斯补充道。

“Beyond linker and payload excellence, we are deeply evaluating a cutting edge innovative capacity expansion intending continuous‑flow conjugation using custom micro‑equipment skids. By holding pH, temperature, stoichiometry, and residence time within tight bands.'

“除了连接子和有效载荷的卓越性能外，我们正在深入评估一项尖端的创新产能扩展计划，旨在通过定制的微型设备滑橇实现连续流动偶联。通过将pH值、温度、化学计量和停留时间控制在严格范围内。”

The integrated offering includes:

集成产品包括：

With Celonic upstream and CARBOGEN AMCIS downstream, teams get one accountable partner. This alliance removes variability and removes handoffs so that such life-saving therapies reach families sooner, across the globe.

通过上游的Celonic和下游的CARBOGEN AMCIS，团队获得了一个负责任的合作伙伴。这一联盟消除了可变性并减少了交接，从而使这些挽救生命的疗法能够更快地惠及全球的家庭。

For high resolution please click the image.

如需高分辨率，请点击图片。

For high resolution please click the images.

请单击图像以获取高分辨率。

About

关于

Celonic Group

赛洛尼克集团

Celonic is a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO). Celonic’s mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion.

Celonic是一家“纯粹的”生物制品合同开发和制造组织（CDMO）。Celonic的使命是帮助其客户，主要是中小型到大型的生物技术公司，通过创新的“下一代”生物处理技术（如工艺强化和全灌注）有效地将挽救生命和改善生命的药物推向市场。

Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic across the two locations..

Celonic在瑞士巴塞尔（总部）拥有一个最先进的开发和创新中心，并在德国海德堡设有临床和商业GMP生产设施。目前，Celonic在这两个地点拥有500多名高素质员工。

About

关于

CARBOGEN AMCIS

卡博根AMCIS

CARBOGEN AMCIS, a Dishman Carbogen Amcis Company, is a global development and manufacturing partner for complex medicines. Specialisms include high-potency APIs, linker and payload chemistry, precise bioconjugation for ADCs and clinical-to-commercial sterile fill-finish. Integrated analytics and CMC/regulatory capabilities reduce handoffs and accelerate timelines, while flow-enabled process design and engineered containment enhance control, throughput and safety at scale.

CARBOGEN AMCIS，作为Dishman Carbogen Amcis公司的一员，是复杂药物的全球开发和制造合作伙伴。专业领域包括高效API、连接子与有效载荷化学、ADC的精准生物偶联以及从临床到商业化的无菌灌装。集成的分析方法和CMC/法规事务能力减少了交接环节并加快了时间表，而流动化学工艺设计和工程化防护措施则增强了规模化生产中的控制、通量和安全性。

Facilities across Europe and Asia support development, clinical supply and commercial manufacture..

欧洲和亚洲的设施支持开发、临床供应和商业制造。

Contacts

联系人

Celonic Group

赛洛尼克集团

Elisa Witt

艾丽莎·维特

Marketing & Communications

市场营销与传播

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

+41 76 588 67 59

+41 76 588 67 59

CARBOGEN AMCIS

卡博根AMCIS

Denise Neufeld

丹尼斯·纽菲尔德

Marketing & Communication Officer

营销与传播专员

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

+41 58 909 0384

+41 58 909 0384

Keywords: International Cooperation; Manufacturing and Industrial Facilities; Biological Products; Drug Development; Cell Line; Bioreactors; Cell Proliferation; Cell Line Development; Cells, Cultured; Productivity; Pharmaceutical Preparations; Pharmaceutical Services; Biotechnology; Switzerland; Celonic Group; CARBOGEN AMCIS; strategic alliance; ADC development; manufacturing platform; CDMO; process development; Active Pharmaceutical Ingredient (API); antibody-drug conjugates (ADCs); payload synthesis; conjugation; sterile fill-finish; GS-CHOvolution™ cell line platform; perfusion-based technologies; linker and payload development; Basel Development Center; Heidelberg GMP site.

关键词：国际合作；制造与工业设施；生物制品；药物开发；细胞系；生物反应器；细胞增殖；细胞系开发；培养细胞；生产力；药品制剂；药品服务；生物技术；瑞士；Celonic集团；CARBOGEN AMCIS；战略联盟；ADC开发；生产平台；CDMO；工艺开发；活性药物成分（API）；抗体药物偶联物（ADC）；有效载荷合成；偶联；无菌灌装；GS-CHOvolution™细胞系平台；基于灌流的技术；连接子与有效载荷开发；巴塞尔开发中心；海德堡GMP基地。

Source: Biotech Newswire

来源：生物技术新闻社